文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

接种 SARS-CoV-2 疫苗后医护人员的疫苗副作用：TüSeRe:exact 研究的数据。

Vaccine Side Effects in Health Care Workers after Vaccination against SARS-CoV-2: Data from TüSeRe:exact Study.

机构信息

Centre for Clinical Transfusion Medicine, 72076 Tübingen, Germany.

NMI Natural and Medical Sciences Institute, University Tübingen, 72770 Reutlingen, Germany.

出版信息

Viruses. 2022 Dec 25;15(1):65. doi: 10.3390/v15010065.

DOI:10.3390/v15010065
PMID:36680106
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9864657/
Abstract

As the Corona Disease 2019 (COVID-19) caused by SARS-CoV-2 persists, vaccination is one of the key measures to contain the spread. Side effects (SE) from vaccination are one of the reasons for reluctance to vaccinate. We systematically investigated self-reported SE after the first, second, and booster vaccinations. The data were collected during the TüSeRe: exact study (Tübinger Monitoring Studie zur exakten Analyse der Immunantwort nach Vakzinierung). Employees of health and research institutions were invited to participate. Study participants were asked to fill out an online questionnaire and report their SE after each dose of SARS-CoV-2 vaccination. A total of 1046 participants (mean age: 44 ± 12.9 years; female, = 815 (78%); male, = 231 (22%)) were included in the analysis. Local and systemic SE were more frequent after receiving the vector-based vaccine ChAdOx1 nCoV-19 in the first vaccination. However, local and systemic SE were more common after receiving mRNA vaccines (BNT162b2, mRNA-1273) in the second vaccination. Compared to the BNT162b2 vaccine, more SE have been observed after receiving the mRNA-1273 vaccine in the booster vaccination. In multivariate analysis, local and systemic side effects were associated with vaccine type, age and gender. Local and systemic SE are common after SARS-CoV-2 vaccines. The frequency of self-reported local and systemic SE differ significantly between mRNA and vector-based vaccines.

摘要

由于严重急性呼吸系统综合征冠状病毒 2 型（SARS-CoV-2）引起的 2019 年冠状病毒病（COVID-19）持续存在，疫苗接种是遏制其传播的关键措施之一。疫苗接种的副作用（SE）是人们不愿接种疫苗的原因之一。我们系统地调查了首次、第二次和加强接种后自我报告的 SE。这些数据是在 TüSeRe：精确研究（Tübinger Monitoring Studie zur exakten Analyse der Immunantwort nach Vakzinierung）中收集的。邀请卫生和研究机构的员工参加。研究参与者被要求填写在线问卷，并报告每次接种 SARS-CoV-2 疫苗后的 SE。共有 1046 名参与者（平均年龄：44 ± 12.9 岁；女性， = 815（78%）；男性， = 231（22%））被纳入分析。在首次接种时，基于载体的 ChAdOx1 nCoV-19 疫苗接种后更常出现局部和全身 SE。然而，在第二次接种时，mRNA 疫苗（BNT162b2、mRNA-1273）接种后更常出现局部和全身 SE。与 BNT162b2 疫苗相比，在加强接种时，接种 mRNA-1273 疫苗后观察到更多的 SE。在多变量分析中，局部和全身副作用与疫苗类型、年龄和性别有关。SARS-CoV-2 疫苗接种后常出现局部和全身 SE。mRNA 和基于载体的疫苗之间自我报告的局部和全身 SE 的频率存在显著差异。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/944f/9864657/5ef330137f21/viruses-15-00065-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/944f/9864657/c6cf983ae585/viruses-15-00065-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/944f/9864657/aac0815eed52/viruses-15-00065-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/944f/9864657/5ef330137f21/viruses-15-00065-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/944f/9864657/c6cf983ae585/viruses-15-00065-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/944f/9864657/aac0815eed52/viruses-15-00065-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/944f/9864657/5ef330137f21/viruses-15-00065-g003.jpg

相似文献

[1]
Vaccine Side Effects in Health Care Workers after Vaccination against SARS-CoV-2: Data from TüSeRe:exact Study.

Viruses. 2022-12-25

[2]
COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study.

Lancet Infect Dis. 2022-7

[3]
Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study.

Lancet Infect Dis. 2021-7

[4]
Reactogenicity among health care workers following a BNT162b2 or mRNA-1273 second dose after priming with a ChAdOx1 nCOV-19 vaccine.

Clin Microbiol Infect. 2022-6

[5]
Patient-reported reactogenicity and safety of COVID-19 vaccinations vs. comparator vaccinations: a comparative observational cohort study.

BMC Med. 2023-9-19

[6]
Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study.

Lancet Respir Med. 2021-11

[7]
Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial.

EBioMedicine. 2022-11

[8]
Waning of humoral immunity depending on the types of COVID-19 vaccine.

Infect Dis (Lond). 2023-3

[9]
Vaccine-Associated Uveitis after COVID-19 Vaccination: Vaccine Adverse Event Reporting System Database Analysis.

Ophthalmology. 2023-2

[10]
Incidence of multiple sclerosis relapses and pseudo-relapses following COVID-19 vaccination.

Mult Scler Relat Disord. 2023-9

引用本文的文献

[1]
Mental symptoms in post-COVID syndrome and post-COVID-19 vaccination syndrome: results of a representative population survey.

Front Public Health. 2025-8-4

[2]
A study on the side effects caused by the Pfizer/BioNTech COVID-19 vaccine: Focus on IgG antibodies and serological biomarkers.

Cent Eur J Immunol. 2024

[3]
Characteristics Associated with COVID-19 Breakthrough Infections after Booster Vaccinations in Healthcare Workers: Insights from the TüSeRe:exact Study.

J Clin Med. 2024-3-9

本文引用的文献

[1]
Comparison of three different COVID-19 vaccine platforms (CoronaVac, BTN162b2, and Ad5-nCoV) in individuals with and without prior COVID-19: Reactogenicity and neutralizing antibodies.

Immunol Lett. 2022-12

[2]
Knowledge, attitudes, perceptions, and COVID-19 hesitancy in a large public university in Mexico city during the early vaccination rollout.

BMC Public Health. 2022-10-4

[3]
Rare Heterogeneous Adverse Events Associated with mRNA-Based COVID-19 Vaccines: A Systematic Review.

Medicines (Basel). 2022-8-11

[4]
Mix-and-Match COVID-19 Vaccinations (Heterologous Boost): A Review.

Infect Dis Rep. 2022-7-20

[5]
Reporting adverse events of ChAdOx1 nCoV-19 coronavirus vaccine (Recombinant) among the vaccinated healthcare professionals: A cross-sectional survey.

Indian J Med Res. 2022-1

[6]
Tolerability and Reactogenicity Profile of mRNA SARS-Cov-2 Vaccines from a Mass Vaccination Campaign in a Tertiary Hospital: Between-Vaccine and Between-Population Prospective Observational Study (VigilVacCOVID Study).

BioDrugs. 2022-7

[7]
A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Moderna COVID-19 Vaccine (mRNA-1273).

Vaccine. 2022-8-19

[8]
Antibody Binding and Angiotensin-Converting Enzyme 2 Binding Inhibition Is Significantly Reduced for Both the BA.1 and BA.2 Omicron Variants.

Clin Infect Dis. 2023-2-8

[9]
Effect of gender, age and vaccine on reactogenicity and incapacity to work after COVID-19 vaccination: a survey among health care workers.

BMC Infect Dis. 2022-3-26

[10]
COVID-19, Vaccines, and Thrombotic Events: A Narrative Review.

J Clin Med. 2022-2-11

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索